Blueprint Medicines' Series C Round

Blueprint Medicines raised a round of funding on November 12, 2014.

Blueprint Medicines is a patient-driven oncology company discovering and developing highly selective kinase inhibitors for genomically defined cancers. Led by a management team and advisors with world…

Articles about Blueprint Medicines' Series C Round: